Related Experiment Videos
Intratracheal N-acetylcysteine use in infants with chronic lung disease
H Bibi1, B Seifert, M Oullette
1Department of Pediatrics, University of Manitoba, Winnipeg, Canada.
Insights
Intratracheal N-acetylcysteine did not improve chronic lung disease in premature infants. This mucolytic agent increased airway resistance and cyanotic spells, suggesting it is not beneficial for these patients.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Pharmacology
Background:
- Chronic lung disease (CLD) is a significant complication in premature infants.
- Increased airway secretions are common in premature infants with CLD.
- Mucolytic agents are sometimes used to manage airway secretions.
Purpose of the Study:
- To assess the efficacy of intratracheal N-acetylcysteine in premature infants with CLD.
- To evaluate the impact of N-acetylcysteine on clinical status, pulmonary function, and gas exchange.
- To determine if N-acetylcysteine improves recovery in this vulnerable population.
Main Methods:
- A randomized, placebo-controlled, crossover trial was conducted.
- Ten mechanically ventilated premature infants with CLD received N-acetylcysteine and saline placebo intratracheally.
- Clinical status, pulmonary function (airway resistance), and gas exchange were monitored.
Main Results:
- N-acetylcysteine caused a significant increase in total airway resistance (59%).
- Two infants experienced increased airway resistance, bradycardia, and cyanosis spells with N-acetylcysteine.
- No overall improvement in clinical status, pulmonary function, or gas exchange was observed with N-acetylcysteine.
Conclusions:
- Intratracheal N-acetylcysteine does not improve clinical condition or recovery in premature infants with CLD.
- N-acetylcysteine administration may increase airway resistance and precipitate adverse events like cyanotic spells.
- Current data do not support the use of N-acetylcysteine as a mucolytic agent in this patient group.
Abstract:
To evaluate the effect of intratracheal administration of N-acetylcysteine (Mucomyst) on the clinical status, pulmonary function and gas exchange in premature infants with chronic lung disease, we conducted a randomized, placebo-controlled, crossover trial. Ten mechanically ventilated infants (gestational age 27 +/- 1 week; postnatal age 22 +/- 6 days) with clinical and radiological evidence of chronic lung disease and increased airway secretion were enrolled in the study. Each infant received tracheal administration of 5% N-acetylcysteine for one week and saline placebo every 4 h for another week. N-acetylcysteine was associated with a 59 +/- 26% increase in total airway resistance by the third day of treatment (p less than 0.01). A two-fold increase in airway resistance associated with an increased frequency of bradycardia and cyanosis spells was seen in two of the infants following three days of N-acetylcysteine administration, with a rapid improvement in their condition when subsequently switched to saline. Overall, N-acetylcysteine administration had no effect on the variables measured. We conclude that intratracheal administration of N-acetylcysteine to liquefy airway mucus neither improves the clinical condition nor hastens recovery in premature infants with chronic lung disease and its administration may lead to increased total airway resistance and cyanotic spells. The present data do not support the use of N-acetylcysteine as a mucolytic agent in premature infants with chronic lung disease.